EULAR 2019: UCB's bimekizumab continues to impress

Bimekizumab is a crucial pipeline drug for UCB (Euronext: UCB) – allowing the company’s to look beyond Cimzia (certolizumab pegol) in immunology – so each successful data read-out is a relief for the Belgian drugmaker.

The latest positive milestone has been announced at EULAR, with new Phase IIb data showing that it delivered improvements in disease activity and in important patient-reported outcomes, such as pain, fatigue, morning stiffness, function and quality of life, for patients with ankylosing spondylitis (AS).

These improvements, which occurred at different doses, are hypothesized to be associated with bimekizumab’s mechanism of action, which potently and selectively neutralizes both interleukin (IL)-17A and IL-17F cytokines.